An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Hyperfine, Inc. to Present at the Oppenheimer 34th Annual Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Hyperfine, Inc. (HYPR) to present at Oppenheimer Healthcare MedTech & Services Conference with a focus on their FDA-cleared portable MR brain imaging system, the Swoop® system.
Positive
None.
Negative
None.
GUILFORD, Conn.--(BUSINESS WIRE)--
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system, today announced plans to present at the upcoming Oppenheimer 34th Annual Healthcare MedTech & Services Conference, taking place virtually. Members of management are scheduled to present on Wednesday, March 13, 2024, at 2:40 pm ET.
A live webcast of the event, as well as an archived recording will be available on the “Investors” section of the company’s website at: investors.hyperfine.io. The webcasts will be archived and available for replay for at least 90 days after the event.
For more information about the Swoop®Portable MR Imaging® system, please visit hyperfine.io.
About Hyperfine, Inc. and the Swoop®Portable MR Imaging® System
Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the world’s first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of care. The Swoop® system received initial U.S. Food and Drug Administration (FDA) clearance in 2020 as a portable magnetic resonance brain imaging device for producing images that display the internal structure of the head where a full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. The Swoop® system has been approved for brain imaging in several countries, including Canada and Australia, has UKCA certification in the United Kingdom, CE certification in the European Union, and is also available in New Zealand.
The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging and data solutions. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. Traditionally, access to costly, stationary, conventional MRI technology can be inconvenient or not available when needed most. With the portable, ultra-low-field Swoop® system, Hyperfine, Inc. is redefining the neuroimaging workflow by bringing brain imaging to the patient’s bedside. For more information, visit hyperfine.io.
Hyperfine, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc.
hyperfine’s mission is to make mri accessible to every patient, regardless of income or resources. anytime. anywhere.hyperfine’s swoop® portable mr imaging system™ addresses limitations of current imaging technologies. swoop wheels directly to a patient’s bedside, where it plugs into a standard electrical outlet and uses an apple ipad® for control. images display within minutes, enabling critical decision-making capabilities across various clinical settings such as neurointensive care units, emergency departments, pediatrics, and more. designed as a complementary system to fixed conventional mri systems, new users can be trained on system operation, device navigation, and safety in about 30 minutes, helping clinicians streamline workflow. the complete swoop™ portable mr imaging system costs less than the annual service contract for most fixed conventional mri systems.in august 2020, swoop received market-ready fda clearance for portable mr imaging of the brain and head for patients of